C.R. Bard (NYSE: BCR) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare C.R. Bard to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Risk and Volatility
C.R. Bard has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, C.R. Bard’s peers have a beta of 1.06, meaning that their average share price is 6% more volatile than the S&P 500.
Valuation & Earnings
This table compares C.R. Bard and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|C.R. Bard||$3.83 billion||$1.18 billion||43.39|
|C.R. Bard Competitors||$827.23 million||$159.50 million||36.89|
C.R. Bard has higher revenue and earnings than its peers. C.R. Bard is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
79.2% of C.R. Bard shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 0.8% of C.R. Bard shares are held by insiders. Comparatively, 11.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares C.R. Bard and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|C.R. Bard Competitors||-127.20%||-36.60%||-10.35%|
This is a summary of current ratings and recommmendations for C.R. Bard and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|C.R. Bard Competitors||174||1133||2482||89||2.64|
C.R. Bard currently has a consensus price target of $282.29, indicating a potential downside of 14.50%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 10.91%. Given C.R. Bard’s peers stronger consensus rating and higher probable upside, analysts clearly believe C.R. Bard has less favorable growth aspects than its peers.
C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.8% and pay out 37.4% of their earnings in the form of a dividend. C.R. Bard has raised its dividend for 45 consecutive years.
C.R. Bard beats its peers on 8 of the 15 factors compared.
C.R. Bard Company Profile
C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.